LET'S KEEP IN TOUCH.
Oops! Something went wrong while submitting the form.
At DNAe we are leading the way in rapid, near-patient sequencing testing that will revolutionize patient care for a range of unmet clinical needs.
Find out more from our Co-Founder, Professor Christofer Toumazou and our CEO, Sam Reed.
DNAe is developing the LiDia-SEQ™ Platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians. The user-friendly system can operate in a variety of hospital environments at the point-of-need, with flexible levels of throughput to match a wide range of clinical demands.
Our initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis.
To follow this, we have a growing pipeline of tests for other healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious diseases and cancer testing and monitoring.
There is a growing urgency to tackle the alarming rise of antimicrobial resistance (AMR). Strong focus is being placed on reducing the overuse and misdirected use of antibiotics. Capable of rapidly diagnosing infections and associated AMR at the point-of-need, our LiDia-SEQ™ sequencing system and BSI/AMR test is uniquely positioned to respond to this challenge.
In September 2016, DNAe was awarded a contract worth up to $51.9M by the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Health and Human Services (HHS), to develop its semiconductor sequencing diagnostic platform initially for antimicrobial resistant infections. We reported successful completion of the first phase of development in late 2018 and are now approaching completion of the second phase.
It can take 2-6 days to diagnose bloodstream infections using a blood culture test. Using our LiDia-SEQ™ sequencing system and BSI/AMR test, this can be achieved in approximately 3-4 hours, directly from raw specimens.
We have pioneered the use of semiconductor sequencing to build a simple-to-use diagnostic platform that delivers rapid results direct-from-specimen. Our LiDia-SEQ™ system performs genomic analysis on a microchip.
We are creating radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. The work we do at DNAe helps save lives, this is a powerful motivator and a fantastic reason to get involved.
Email: contact@dnae.com
Switchboard: +44 (0)20 7036 2100
Twitter: @dna_electronics
DNAe Group Holdings Ltd
Scale Space
58 Wood Lane
London
W12 7RZ
United Kingdom
DNA Electronics, Inc.
1891 Rutherford Road
Suite 100
Carlsbad, CA 92008
USA
+1 (760) 444-9410
Email: contact@dnae.com
Switchboard: +44 (0)20 7036 2100
Twitter: @dna_electronics
DNAe Group Holdings Ltd
Scale Space
58 Wood Lane
London
W12 7RZ
United Kingdom
DNA Electronics, Inc.
1891 Rutherford Road
Suite 100
Carlsbad, CA 92008
USA
+1 (760) 444-9410
Email: contact@dnae.com
Switchboard: +44 (0)20 7036 2100
Twitter: @dna_electronics
DNAe Group Holdings Ltd
Scale Space
58 Wood Lane
London
W12 7RZ
United Kingdom
DNA Electronics, Inc.
1891 Rutherford Road
Suite 100
Carlsbad, CA 92008
USA
+1 (760) 444-9410
